{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:37:21Z","timestamp":1763105841349,"version":"3.41.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The majority of new bladder cancer diagnoses are non-muscle invasive bladder cancer (NMIBC). For patients with intermediate-risk and high-risk NMIBC, the preferred treatment after transurethral tumor resection is bacillus Calmette\u2013Gu\u00e9rin (BCG) intravesical therapy; however, some patients receiving BCG do not respond and are at risk for recurrence and progression to muscle invasive disease. Currently, there is a lack of bladder-sparing therapies for patients that do not respond to BCG therapy. This review highlights recent advances in bladder-sparing therapies for NMIBC that do not respond to BCG therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Several clinical trials have emerged over the past several years using novel agents. Systemic immunotherapy with pembrolizumab has shown promising activity, and recently gained FDA approval for use in BCG-unresponsive NMIBC. Gene therapy using Nadofaragene firadenovec, a replication-deficient adenoviral vector delivering interferon (IFN) alfa, shows durable results and is pending regulatory approval. Several other agents are on the horizon and there will likely be an emergence of therapies over the next several years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Patients with NMIBC that do not respond to BCG therapy are at high risk for progression to muscle invasive disease. Bladder-sparing therapeutic options for these patients are sparse but now include pembrolizumab and several other potential options are emerging. These bladder-sparing therapies will benefit patients unwilling or unable to undergo radical cystectomy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000587","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T11:32:58Z","timestamp":1640863978000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Emerging treatment options for bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer"],"prefix":"10.1097","volume":"16","author":[{"given":"Andrea","family":"Kokorovic","sequence":"first","affiliation":[{"name":"University of Montreal Hospital Center (CHUM), Montreal Cancer Institute\/CRCHUM, Montreal, Quebec"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Ory","sequence":"additional","affiliation":[{"name":"Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"University of Montreal Hospital Center (CHUM), Montreal Cancer Institute\/CRCHUM, Montreal, Quebec"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"R1-20250525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R2-20250525","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"R3-20250525","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-5347(05)67972-4","article-title":"Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome","volume":"163","author":"Herr","year":"2000","journal-title":"J Urol"},{"key":"R4-20250525","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.urology.2006.03.062","article-title":"Clinical model of lifetime cost of treating bladder cancer and associated complications","volume":"68","author":"Avritscher","year":"2006","journal-title":"Urology"},{"key":"R5-20250525","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"R6-20250525","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"R7-20250525","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"R8-20250525","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.juro.2013.11.005","article-title":"5-year outcome of a randomized prospective study comparing bacillus Calmette-Gu\u00e9rin with epirubicin and interferon-alpha2b in patients with T1 bladder cancer","volume":"191","author":"Hemdan","year":"2014","journal-title":"J Urol"},{"key":"R9-20250525","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer"},{"key":"R10-20250525","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high-risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"R11-20250525","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Gu\u00e9rin-refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"R12-20250525","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"R13-20250525","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter, phase 2 trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"R14-20250525","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Gu\u00e9rin failure pattern on subsequent response to bacille Calmette-Gu\u00e9rin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"R15-20250525","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase 2 trial of intravesical gemcitabine in patients with nonmuscle-invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu\u00e9rin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"R16-20250525","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle-invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"key":"R17-20250525","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of nonmuscle-invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"key":"R18-20250525","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multiinstitution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"R19-20250525","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus Calmette\u2013Gu\u00e9rin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"Decastro","year":"2020","journal-title":"J Urol"},{"key":"R20-20250525","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent nonmuscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"key":"R21-20250525","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase 3 KEYNOTE-045 trial of pembrolizumab vs. paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of followup","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"R22-20250525","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"R23-20250525","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk nonmuscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicenter, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"R24-20250525","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for nonmuscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"R25-20250525","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"(Suppl 4)","key":"R26-20250525","article-title":"PD03-02 phase 3 results of Vicinium in bcg-unresponsive nonmuscle invasive bladder cancer","volume":"203","author":"Shore","year":"2020","journal-title":"J Urol"},{"issue":"(Suppl 6)","key":"R27-20250525","article-title":"Phase II\/III clinical results of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients","volume":"39","author":"Chamie","year":"2021","journal-title":"J Clin Oncol"},{"key":"R28-20250525","doi-asserted-by":"crossref","first-page":"850.e9","DOI":"10.1016\/j.urolonc.2020.06.031","article-title":"Sequential administration of bacillus Calmette-Gu\u00e9rin (BCG) and electromotive drug administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscleinvasive bladder cancer after BCG failure","volume":"38","author":"Juvet","year":"2020","journal-title":"Urol Oncol"},{"key":"R29-20250525","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","article-title":"Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Gu\u00e9rin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette-Gu\u00e9rin therapy (HYMN): A phase III, open-label, randomised controlled trial","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"R30-20250525","doi-asserted-by":"crossref","first-page":"17588359211039052","DOI":"10.1177\/17588359211039052","article-title":"Novel and emerging approaches in the management of nonmuscle invasive urothelial carcinoma","volume":"13","author":"Yassaie","year":"2021","journal-title":"Ther Adv Med Oncol"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T18:01:46Z","timestamp":1748196106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000587","relation":{},"ISSN":["1751-4258","1751-4266"],"issn-type":[{"type":"print","value":"1751-4258"},{"type":"electronic","value":"1751-4266"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}